Eagle Pharma launches new suit over leukaemia drug

Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eagle Pharmaceuticals asserts new patents with trio of lawsuits over cancer drug

23 January 2024 Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031.

Americas

Teva and Eagle try to block Bendeka generic

1 July 2021 Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Eagle Pharma launches new suit over leukaemia drug

More on this story

Editor's picks

Editor's picks

More features